Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Beam Therapeutics

Beam Therapeutics (NASDAQ: BEAM) insider transactions

In the twelve months to 10 November 2026, executives and directors of Beam Therapeutics reported 31 open-market sales of 631,653 shares ($19.7m) and 0 open-market purchases, by 7 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Beam Therapeutics shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
16 October 2026Evans John M.CEOOption exercise, 10b5-1 plan+25,000$1.031,072,205Form 4
16 October 2026Evans John M.CEOOpen-market sale, 10b5-1 plan−25,000$23.981,047,205Form 4
15 October 2026Evans John M.CEOOption exercise, 10b5-1 plan+25,000$1.031,072,205Form 4
15 October 2026Evans John M.CEOOpen-market sale, 10b5-1 plan−25,000$23.571,047,205Form 4
1 October 2026Cavanagh Bethany JSVP, Finance and TreasurerOpen-market sale, 10b5-1 plan−187$24.4150,984Form 4
24 September 2026Ciaramella GiuseppePresidentGift−123,407—130,504Form 4
27 July 2026Simon AmyChief Medical OfficerOpen-market sale−16,667$25.7485,696Form 4
30 June 2026Simon AmyChief Medical OfficerOpen-market sale−373$34.73102,363Form 4
30 June 2026Evans John M.CEOOption exercise+25,000$1.031,072,205Form 4
30 June 2026Evans John M.CEOOpen-market sale−23,100$34.261,049,105Form 4
30 June 2026Evans John M.CEOOpen-market sale−1,900$34.841,047,205Form 4
29 June 2026Evans John M.CEOOption exercise+18,663$0.671,065,868Form 4
29 June 2026Evans John M.CEOOption exercise+6,337$1.031,072,205Form 4
29 June 2026Evans John M.CEOOpen-market sale−13,421$35.131,058,784Form 4
29 June 2026Evans John M.CEOOpen-market sale−11,579$35.911,047,205Form 4
26 June 2026Fmr Llc—Open-market sale−251,488$35.26854,583Form 4
25 June 2026Fmr Llc—Open-market sale−33,372$35.121,106,071Form 4
17 June 2026Ciaramella GiuseppePresidentOption exercise+6,505$0.67224,911Form 4
17 June 2026Ciaramella GiuseppePresidentOption exercise+29,000$1.03253,911Form 4
1 April 2026Ciaramella GiuseppePresidentOpen-market sale−11,810$24.58218,406Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Beam Therapeutics page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.